While some aspects of the immunolabelling of sortilin and syndecan-1 in LNCaP cells were consistent with that observed in well-formed glands, and PC3 cells were mostly representative of the immunohistochemistry (IHC) in poorly-formed glands (Fig. 1), the LNCaP and PC3 cell lines have limitations as models of early and late stage disease as they were both derived from patients with metastatic disease (there is no commercially available cell line model of primary prostatic adenocarcinoma20). The gene discussed is SORT1; the disease is metastatic neoplasm.